Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q2 2017 · 10-Q
Revenue$0.00$0.00no prior Q2 2016 on file Net Income-$1.89M-$1.89MN/M vs Q2 2016 EPS Diluted-$0.22-$0.22N/M vs Q2 2016 Operating Income-$2,393,242N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
derived
ended Jun 30, 2017 · filed Aug 7, 2017 · 38 d after period end